Health Boards
This retrospective cohort study evaluated the clinical outcomes of HIV-positive patients undergoing anti-IL-23 therapy in real-world settings at the Dermatology Units of four leading reference centres in Northern Italy for the treatment of psoriasis.
Source: onlinelibrary.wiley.com
*Funding: The authors received no specific funding for this work.
Tremfya (guselkumab)
Skyrizi (risankizumab)
Quote:
HIV-positive patients with psoriasis often face delays in accessing biologic therapies due to their exclusion from clinical trials and concerns about the impact of immunomodulatory drugs on viral replication.
Anti-IL-23 therapies, such as risankizumab and guselkumab, have shown great promise thanks to their strong efficacy and favourable safety profiles.
A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis.
Source: onlinelibrary.wiley.com
*Funding: The authors received no specific funding for this work.
Tremfya (guselkumab)
Skyrizi (risankizumab)